A study in sarcoma and melanoma showed circadian rhythms in VEGF expression are regulated by Period and Cryptochrome1, and in vivo chronotherapeutic administration of anti-angiogenic agents during early light phase decrease tumor growth to a greater degree than administration during early dark phase (69). This evidence concerns the gene VEGFA and neoplasm.